title: NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.
authors.forename: Sally
authors.initials: S
authors.lastname: Doss
authors.forename: Zoe
authors.initials: Z
authors.lastname: Garrett
authors.forename: Frances
authors.initials: F
authors.lastname: Sutcliffe
authors.forename: Andrew
authors.initials: A
authors.lastname: Stevens
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000458:organization & administration; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016019:Survival Analysis; D006113:United Kingdom
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab